



The Biotech Growth Trust

Investor Presentation

June 2011

This document does not constitute an offer of securities. Such an offer will only be made by means of a Confidential Memorandum to be furnished to investors at a later date. The manager may make changes to this document without notification.

OrbiMed Overview


- Premier investment firm focused exclusively on the healthcare sector, with approximately \$6 billion in assets under management
- Worldwide health sciences investments across the industry life cycle, from seed-stage venture capital to large publicly-traded companies
- Offices in New York, San Francisco, Shanghai, Mumbai and Tel Aviv
- 42 investment professionals across five offices provide a potent combination of scientific expertise, analytical skills and industry experience
- Proven investment performance over a significant period of time
- Stable organization with consistent strategy and leadership for 15+ years

Key Drivers for BIOG Performance

- Capitalize on historic low valuations of major biotech, which are still delivering mid-teens earnings growth
 - ▶ Focus on companies with next-generation products to replace maturing revenues
- Invest in emerging biotech companies with newly launched products or ones in late-stage development
 - ▶ Focus on companies that make likely M&A candidates or are about to become profitable
- Invest in the most promising early-stage emerging companies with novel therapeutic candidates
 - ▶ Focus on companies whose drug candidates are poised to deliver positive clinical data
- Worldwide strategy

Portfolio Exposure

As of 31 May 2011



**Percentages based on gross exposure.*


BIOG Holdings

As of 31 May 2011

	Market Price \$ Millions	Pct. Value		Market Price \$ Millions	Pct. Value
UNITED STATES			INTERNATIONAL		
Emerging Biotechnology			Europe		
Affymetrix Inc	5.5	2.6	Emerging Biotechnology		
Alexion Pharmaceuticals Inc	3.5	1.6	Bavarian Nordic A/S	3.0	1.4
Allos Therapeutics Inc	3.1	1.4	Medivir AB	3.4	1.6
Anadys Pharmaceuticals Inc	1.2	0.6	Stratec Biomedical AG	<u>2.3</u>	<u>1.1</u>
Arqule Inc	5.2	2.5		8.7	4.1
Aveo Pharmaceuticals Inc	0.6	0.3	Major Capitalization		
BioMarin Pharmaceutical Inc	6.6	3.1	Shire PLC ADR	13.9	6.5
Cubist Pharmaceuticals Inc	4.3	2.0	Europe Subtotal		
Dendreon Corp	2.2	1.0		22.6	10.6
Exact Sciences Corp	4.0	1.9	Far East		
Fluidigm Corporation	3.9	1.8	Emerging Biotechnology		
Human Genome Sciences Inc	3.9	1.8	3SBio Inc ADS	5.4	2.5
Idenix Pharmaceuticals Inc	3.3	1.6	Caduceus Asia Partners	<u>2.0</u>	<u>0.9</u>
Incyte Corp	9.2	4.3		7.4	3.4
Insmed Inc	0.1	0.1	Far East Subtotal		
InterMune Inc	2.6	1.2		7.4	3.4
KV Pharmaceutical Co	2.8	1.3	INTERNATIONAL TOTAL		
Medivation Inc	2.2	1.0		30.0	14.0
NPS Pharmaceuticals Inc	3.0	1.4	Cash		
Nanosphere	1.3	0.6		(22.1)	(10.4)
Oncothyreon Inc	2.7	1.3			
Onyx Pharmaceuticals Inc	3.3	1.6			
Pharmacyclics Inc	7.8	3.6			
Pharmasset Inc	9.5	4.5			
Regeneron Pharmaceuticals Inc	4.4	2.1			
Targacept Inc	6.6	3.1			
Tranzyme Inc	3.3	1.6			
Trius Therapeutics Inc.	4.1	1.9			
United Therapeutics Corp	5.5	2.6			
Vivus Inc	2.3	1.1			
Warner Chilcott PLC	6.8	3.2			
YM Biosciences Inc	<u>0.2</u>	<u>0.1</u>			
	125.0	58.8			
Major Capitalization					
Amgen Inc	6.6	3.1			
Biogen Idec Inc	7.1	3.3			
Celgene Corp	7.5	3.5			
Gilead Sciences Inc	16.9	7.9			
Illumina Inc	8.4	4.0			
Life Technologies Corporation	9.6	4.5			
Perrigo Co	4.9	2.3			
Teva Pharmaceutical Industries	11.0	5.2			
Thermo Fisher Scientific Inc	<u>7.9</u>	<u>3.7</u>			
	79.9	37.5			
UNITED STATES TOTAL	204.8	96.3	TOTAL PORTFOLIO	212.8	100.0

BIOG Performance in Calendar Year to Date

31 December 2010 through 31 May 2011



Explanation of Recent Performance

- The Trust has slightly outperformed the benchmark NBI index in the calendar year to date
- Biotech performed well in general over the period, led by strong gains in a few small-cap names
 - Positive results from a pivotal trial of Biogen Idec's BG-12 in multiple sclerosis (BIIB up 41%)
 - Positive abstract on Pharmasset's nuc-nuc combo at EASL (VRUS up 135%)
 - Patent settlement between Cubist and Teva (CBST up 80%)
- New additions of small-cap names through PIPEs and registered direct offerings have done particularly well (Idenix up 70%, Oncothyreon up 62%, Trius Therapeutics up 43%)

Trust Performance vs. Benchmark


Periods Ending 31/05/11	Calendar 2011 YTD	Fiscal 2011 (03/10- 03/11)	Fiscal 2010 (03/09- 03/10)	3-year annualized return	Since OrbiMed Inception (18/05/05)
BIOG NAV (£)	12.3%	1.9%	33.4%	21.4%	98.5%
NASDAQ Biotech Index (£)	11.0%	4.8%	29.4%	18.6%	85.6%
Excess Returns (£)	1.3%	-2.9%	3.9%	2.7%	12.9%
Est. Currency Impact on NAV	-6.1%	-5.9%	-8.3%	7.3%	21.0%
MSCI World Index (£)	1.5%	7.3%	43.4%	4.5%	50.9%
FTSE All-Share Index (£)	1.9%	5.4%	46.7%	0.4%	26.7%
Russell 2000 Index (£)	2.7%	17.5%	51.1%	10.9%	56.1%

Source: OrbiMed Advisors

Healthcare Sector Outperforming Year-to-Date

Rally occurring after extended period of underperformance

- The prospect of healthcare reform served as an overhang on the healthcare sector once President Obama made it a legislative priority in Feb. 2009, leading to **underperformance** of healthcare stocks
- On March 23, 2010 President Obama signed the long awaited healthcare reform bill into law, increasing coverage to an additional 30+ million Americans starting in 2014
- Once the bill was passed, healthcare stocks were impacted by the legislation's upfront costs and fees to the healthcare industry
- Now that investors have incorporated those costs into their estimates, healthcare shares are on a rebound relative to the general market




*As of 5/31/11


Long Term Historically Attractive Entry Point

Valuations have contracted on an absolute and relative basis

Attractive Valuations Create Long Opportunities



Healthcare PE Relative to S&P PE at Historical Low



- Valuations across the healthcare sector have declined to historical lows after a nearly 10 year period of underperformance
- Underperformance of the healthcare sector continued through 2010 into early 2011
- We believe this performance and valuation differential provides a significant opportunity to earn near-term returns across a variety of long positions

M&A Remains a Secular Theme for Healthcare

Big pharma pursuing acquisitions to replace lost revenues and refill pipelines

Announced	Target	Acquirer	Deal Size	Premium Paid
05/24/2011	Sanitas	Valeant	€364 million	82%
05/09/2011	Elan's EDT Business	Alkermes	\$960 million	NA
05/02/2011	Cephalon	Teva	\$6.8 billion	39% ⁽¹⁾
04/11/2011	American Medical Systems	Endo	\$2.9 billion	34%
04/05/2011	Inspire	Merck	\$340 million	26%
03/29/2011	ChemGenex	Cephalon	\$231 million	59%
02/22/2011	Clinical Data	Forest Labs	\$1.2 billion + CVR	7% ⁽²⁾ + CVR
12/01/2010	Eurand	Axcan	\$551 million	9%
08/03/2010	Movetis	Shire	\$390 million	74%
10/22/10	Clariant	General Electric	\$580 million	34%
09/17/10	Crucell	Johnson & Johnson	€1.75 billion ⁽³⁾	58%
08/30/10	Genzyme	Sanofi-Aventis	\$20.1 billion + CVR	37% ⁽⁴⁾ + CVR
06/30/10	Abraxis BioScience	Celgene	\$2.9 billion + CVR	14% + CVR
04/12/10	Javelin Pharmaceuticals	Hospira	\$140 million	64%
03/09/10	Facet Biotech	Abbott Laboratories	\$402 million	206%
03/01/10	OSI Pharmaceuticals	Astellas Pharma	\$2.9 billion	41%
09/03/09	Sepracor	Dainippon Sumitomo	\$2.3 billion	28%
07/22/09	Medarex	Bristol Myers	\$2.4 billion	90%
07/14/09	Noven Pharmaceuticals	Hisamitsu	\$428 million	22%
05/21/09	Cougar Biotechnology	Johnson & Johnson	\$970 million	16%
03/12/09	CV Therapeutics	Gilead	\$1.4 billion	25%
02/27/09	Arana Therapeutics	Cephalon	\$210 million	69%

(1) Premium to the last closing price before receiving an unsolicited offer from Valeant on 03/30/2011.

(2) Premium to the average price since the first day after announcing the approval of Viibryd and that it was considering a potential sale.

(3) Represents value paid for 82% of Crucell that J&J did not already own.

(4) Offer premium to price on 07/22/10, the first day prior to rumors of a potentially unsolicited bid emerged.

Source: OrbiMed Advisors



Acquisition Candidates in BIOG

Company	Asset	Potential Acquiror
3SBio	Epiao	Amgen, Genzyme, Roche
Allos Therapeutics	Folotyn	Biogen Idec, Genzyme
Anadys Pharmaceuticals	ANA598, ANA773	Roche, Bristol-Myers Squibb, Merck
Biogen Idec	Rituxan, Tysabri, Pipeline	Big Pharma
BioMarin Pharmaceutical	Phenoptin, Aldurazyme, Aryplase	Genzyme, Shire
Cubist Pharmaceuticals	Cubicin	Any Pharma or Biotech w/ a hospital salesforce
Dendreon	Provenge	Big Biotech, Big Pharma
Human Genome Sciences	Benlysta	Big Biotech, Big Pharma
Incyte	INCB '424	Big Biotech, Big Pharma
Pharmacyclics	PCY-32765	Big Biotech, Big Pharma
Pharmasset	RG7128, PSI-7977, PSI-938	Roche
Shire	Vyvanse, Elaprase, Vpriv	Big Pharma

Source: OrbiMed Advisors

Innovation Lies in Small-to-Mid-Cap Biotech

BIOG well-positioned to capture value creation from innovation

- Identifying innovative therapies and the next product cycle are key to investing in healthcare, and the innovation is primarily occurring among small-to-mid-cap companies
- Several blockbuster drugs being developed by biotech companies have recently launched or are about to be launched in the near future, which should be positive catalysts for the sector

Product	Marketer	Indication	Launch Year	Revenue Potential
Tyvaso	United Therapeutics	Pulmonary Hypertension	2009	\$200 million
Ampyra	Acorda	Multiple Sclerosis	2009	\$500 million
Cinryze	ViroPharma	Hereditary Angioedema	2009	\$250 million
Xiaflex	Auxilium	Dupuytren's Contracture	2010	\$350 million
Provenge	Dendreon	Prostate cancer	2010	\$2 billion
Xgeva	Amgen	Skeletal-related Events in Cancer	2011	\$1.5 billion
Benlysta	HGS/Glaxo	Lupus	2011	\$2 billion
Telaprevir	Vertex	Hepatitis C	2011	\$5 billion
Eylea	Regeneron	Wet AMD	2011	\$750 million
Adcetris	Seattle Genetics	Hodgkin's Lymphoma	2011	\$350 million
Ruxolitinib	Incyte	Myelofibrosis	2011	\$1 billion
Qnexa	Vivus	Obesity	2012	\$1 billion
BG-12	Biogen Idec	Multiple Sclerosis	2012	\$2 billion

Source: OrbiMed Advisors

Catalysts and Newsflow for the Next 6 Months

Plenty of catalysts to drive momentum in the sector

- **Pivotal data expected soon:**

- ▶ Genzyme's Lemtrada (Multiple sclerosis)
- ▶ Nabi's NicVAX (Smoking cessation)
- ▶ AVEO's Tivozanib (Renal cell cancer)
- ▶ Exelixis' Cabozantinib (Thyroid cancer)

- **Significant regulatory decisions expected:**

- ▶ Alexion's Soliris (Hemolytic uremic syndrome)
- ▶ Celgene's Istodax (PTCL)
- ▶ Regeneron's VEGF-TRAP Eye (AMD)
- ▶ SGEN's SGN-35 (Hodgkin's lymphoma)
- ▶ Pain Therapeutics' Remoxy (Pain)
- ▶ Gilead's TMC278 + Truvada (HIV)
- ▶ Shire's Firazyr (HAE)
- ▶ Transcept's Intermezzo (Insomnia)
- ▶ Incyte's Ruxolitinib (Myelofibrosis)

- **Upcoming medical conferences**



(ALKS / AMLN /
DARA / GILD /
LXX)

The logo for Eular, consisting of the word 'eular' in a white, lowercase, sans-serif font centered within a dark blue rectangular box.

(BCRX / RDEA)

Investment Outlook


- Now that healthcare reform legislation has passed, we believe healthcare is poised to outperform the general markets in the near-term. The fund is levered to take advantage of this expected outperformance.
- On a historical basis, biotech multiples are at the lowest levels in over a decade.
- Several clinical and regulatory catalysts are due to occur over the next 6 months, and there are a number of blockbuster drugs due to be introduced soon.
- The pace of M&A should remain robust. BIOG has benefited from this M&A activity historically and will continue to do so in the future.



Appendix


BIOG Performance During OrbiMed Tenure

18 May 2005 through 31 May 2011




Differentiation between BIOG and WWH

WWH



BIOG



*As of 5/31/11